(Tromsø, 19 May 2017) Biotec Pharmacon ASA's ("Biotec", OSE: BIOTEC) subsidiary
Biotec BetaGlucans has today filed an appeal for rejection of UK Drug Tariff
reimbursement
With support from external advisors, Biotec has evaluated the decision by the
Drug Tariff authority under NHS to reject the application for remuneration of
Woulgan for wound treatment in UK, and concluded that there are good reasons for
appeal within the framework of NHS' own guidelines.
-"We have consulted with specialist UK healthcare lawyers regarding the
application. Having considered our application and correspondence with the NHS,
they have advised us that there are grounds for an appeal which is in line with
our own opinion of the matter", says Svein Lien, CEO of Biotec Pharmacon.
The appeal will be reviewed by a separate NHS panel according to predefined
criteria. The process does not allow Biotec to submit any further documentation
while the appeal is being processed. According to the NHS guidance to
manufacturers, Biotec should expect a decision by the appeal board within 3
months from submission.
If the appeal is positive, then the Drug Tariff will review the application
again, taking into account any guidance from the appeal panel.
For additional information,
Svein Lien, CEO, +47 922 89 323, svein.lien@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, a premium priced product in the
advanced wound care market. ArcticZymes develops, produces and markets enzymes
of marine origin used in molecular DNA technologies and diagnostics,
representing growth markets where rapid technological developments are creating
a strong demand for new and improved enzymes.